These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 37256791)

  • 1. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
    Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
    Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
    Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
    Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.
    Takata H; Shimizu T; Yamade R; Elsadek NE; Emam SE; Ando H; Ishima Y; Ishida T
    J Control Release; 2023 Aug; 360():285-292. PubMed ID: 37355210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer.
    Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A
    Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
    Wang X; Ishida T; Kiwada H
    J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients.
    Miao G; He Y; Lai K; Zhao Y; He P; Tan G; Wang X
    J Control Release; 2023 Nov; 363():12-26. PubMed ID: 37717659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine).
    Bavli Y; Chen BM; Gross G; Hershko A; Turjeman K; Roffler S; Barenholz Y
    J Control Release; 2023 Feb; 354():316-322. PubMed ID: 36549393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomes with Low Levels of Grafted Poly(ethylene glycol) Remain Susceptible to Destabilization by Anti-Poly(ethylene glycol) Antibodies.
    Chen BM; Chen E; Lin YC; Tran TTM; Turjeman K; Yang SH; Cheng TL; Barenholz Y; Roffler SR
    ACS Nano; 2024 Aug; 18(33):22122-22138. PubMed ID: 39119697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
    Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
    Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
    El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
    Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
    Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
    Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells.
    Shimizu T; Mima Y; Hashimoto Y; Ukawa M; Ando H; Kiwada H; Ishida T
    Immunobiology; 2015 Oct; 220(10):1151-60. PubMed ID: 26095176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T; Atobe K; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.
    Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M
    J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine.
    Ju Y; Lee WS; Pilkington EH; Kelly HG; Li S; Selva KJ; Wragg KM; Subbarao K; Nguyen THO; Rowntree LC; Allen LF; Bond K; Williamson DA; Truong NP; Plebanski M; Kedzierska K; Mahanty S; Chung AW; Caruso F; Wheatley AK; Juno JA; Kent SJ
    ACS Nano; 2022 Aug; 16(8):11769-11780. PubMed ID: 35758934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity.
    Mima Y; Abu Lila AS; Shimizu T; Ukawa M; Ando H; Kurata Y; Ishida T
    J Control Release; 2017 Mar; 250():20-26. PubMed ID: 28179196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
    El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T
    J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
    Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.
    Kaminskas LM; McLeod VM; Porter CJ; Boyd BJ
    J Pharm Sci; 2011 Nov; 100(11):5069-77. PubMed ID: 21721002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.